Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer

[1]  M. Okada,et al.  [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[2]  M. Czuczman,et al.  Bendamustine is effective therapy in patients with rituximab‐refractory, indolent B‐cell non‐Hodgkin lymphoma , 2009, Cancer.

[3]  L. Tremmel,et al.  Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Samuel Leung,et al.  Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2008, Clinical Cancer Research.

[5]  Rob Jones,et al.  Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study. , 2008, European journal of cancer.

[6]  Jacques Corbeil,et al.  Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents , 2008, Clinical Cancer Research.

[7]  A. Tutt,et al.  Triple negative tumours: a critical review , 2007, Histopathology.

[8]  D. Wallwiener,et al.  Salvage chemotherapy for metastatic breast cancer: results of a phase II study with bendamustine. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  D. Gandara,et al.  Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. , 2007, Clinical lung cancer.

[10]  M. Aubry,et al.  Translational correlates, including outcome for patients with ER-/PR-/HER2- (triple negative (TNeg)) disease from N0234, a phase II trial of gemcitabine and erlotinib for pts with previously treated metastatic breast cancer (MBC) , 2007 .

[11]  J. Milanowski,et al.  Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Wolfgang Heller,et al.  Triple-negative breast cancer: therapeutic options. , 2007, The Lancet. Oncology.

[13]  J. Weidhaas,et al.  Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Lakhani,et al.  Metaplastic breast carcinomas are basal‐like tumours , 2006, Histopathology.

[15]  B. Overmoyer,et al.  Toxicity and outcome data in a phase II study of weekly docetaxel in combination with erlotinib in recurrent and/or metastatic breast cancer (MBC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Lakhani,et al.  Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis , 2005, Breast Cancer Research.

[17]  Xin Li,et al.  TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Souchon,et al.  Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC , 2005, Anti-cancer drugs.

[19]  E. Perez,et al.  N0234: Phase II study of erlotinib (OSI-774) plus gemcitabine as first-or second-line therapy for metastatic breast cancer (MBC) , 2005 .

[20]  M. Kris,et al.  Pulsatile Administration of the Epidermal Growth Factor Receptor Inhibitor Gefitinib Is Significantly More Effective than Continuous Dosing for Sensitizing Tumors to Paclitaxel , 2005, Clinical Cancer Research.

[21]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[22]  K. Höffken,et al.  Pneumocystis carinii pneumonia as a complication of bendamustine monotherapy in a patient with advanced progressive breast cancer , 2003, Journal of Cancer Research and Clinical Oncology.

[23]  R. Semrau,et al.  Regression of brain metastases from breast carcinoma after chemotherapy with bendamustine , 2002, Journal of Cancer Research and Clinical Oncology.

[24]  A. Ganser,et al.  Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumours. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  Ian O Ellis,et al.  Prognostic markers in triple‐negative breast cancer , 2007, Cancer.

[26]  L. Tanoue,et al.  Erlotinib in Previously Treated Non-Small-Cell Lung Cancer , 2007 .

[27]  K. Höffken,et al.  Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia , 2001, Journal of Cancer Research and Clinical Oncology.

[28]  S. Seeber,et al.  Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study , 1998, Journal of Cancer Research and Clinical Oncology.